Primary Aldosteronism Market Global Analysis, Size, Share, Trends, And Forecast 2021 to 2027

 Primary Aldosteronism Market research report, Type (type I, type II), Indication (heart attack, kidney failure, stroke), by Diagnosis (blood test, imaging), Treatment (surgery, aldosterone antagonists), End User (hospitals) - forecast till 2027

Market Highlights:

Increasing prevalence of primary aldosteronism, growing geriatric population, rising number of obese individuals in the developing as well as the developed regions and increasing consumption of alcohol are estimated to drive the market growth during the forecast period. Moreover, rising per capita healthcare expenditure boosts the growth of primary aldosteronism. However, lack of awareness and risks of excessive bleeding, infection, anesthesia reaction by the corrective surgeries will restrain the market growth during the projected period.

Get Sample Report at https://www.marketresearchfuture.com/sample_request/5522

Key Players:

The key players for the global primary aldosteronism market are Pfizer Inc. (U.S.), Sun Pharmaceutical Industries Ltd.  (India), Bristol Laboratories Ltd (England), CMP Pharma. (U.S.), Koninklijke Philips N.V. (The Netherlands), GE Healthcare (U.K), Siemens AG (Germany), Shimadzu Corporation (Japan), Canon Inc. (Japan), and others.

Segmentation:

The global Primary Aldosteronism Treatment Market Growth is segmented on the basis of type, indications, diagnosis, treatment, and end users. On the basis of type, the market is segmented into Type I, and Type II. On the basis of indications, the market is categorised into heart attack, kidney failure, stroke, and others. On the basis of diagnosis, the market is segmented into blood test, imaging, and others. The blood test segment is sub-segmented into aldosterone profiling, renin profiling, and others. The imaging segment is sub-segmented into computed tomography (CT), positron emission tomography (PET), and others. On the basis of end users, the market is segmented into surgery, aldosterone antagonists, and others. The aldosterone antagonists is sub-segmented into spironolactone, eplerenone, and others.

Access Report Deatails @ https://www.marketresearchfuture.com/reports/primary-aldosteronism-market-5522

Regional Analysis:

America dominates the global primary aldosteronism market. Presence of a well-developed healthcare sector and huge patient population within the region enables the Americas to hold the largest share of the market. Moreover, changing lifestyle followed by the increasing healthcare expenditure boosts the market growth within the region. Europe is the second largest market for the primary aldosteronism. Factors such as availability of funds for research and huge patient population followed by government support for research & development drives the market within the region. Asia Pacific is the fastest growing region for the market. Presence of a huge patient population and continuously developing economies like India and China within the region enable the Asia Pacific region to be the fastest growing. However, the Middle East & Africa region has the least share in the global market. Presence of poor economies, stringent government policies, and lack of healthcare services especially within the African region restrains the market growth within the region.

About US:

Market Research Future (MRFR) enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.

Contact Us:

Market Research Future

Office No. 528, Amanora Chambers

Magarpatta Road, Hadapsar,

Pune - 411028

Maharashtra, India

Phone: +1 646 845 9312

Email: sales@marketresearchfuture.com

Global Infectious Disease Treatments Market 2021 by manufacturers, Demand, application, and region 2027

 Infectious Disease Treatments Market Report include on MarketReseacrhFuture.com with Exhaustive Study the Report Focuses on Newer Drugs and Innovations in Chemical Compounds, Vaccines and Biologicals and Diagnostic Kits, Recently Launched or in Development.

Key Players:

Novartis AG (Switzerland), Gilead (U.S.), Janssen Pharmaceutical, Inc. (Belgium), F. Hoffmann-La Roche Ltd. (Germany), AbbVie Inc. (U.S.), GlaxoSmithKline plc (U.K), BioCryst Pharmaceuticals (U.S.), Merck & Co., Inc. (U.S.), and Boehringer Ingelheim GbH (Germany) are some of the prominent players at the forefront of competition in the infectious disease treatment market and are profiled in MRFR Analysis.

Get Sample Report at https://www.marketresearchfuture.com/sample_request/1626

Global Infectious Disease Treatment Market - Overview

The global Infectious Disease Treatments Market Share  is growing mainly due to the rising prevalence of infectious diseases. According to a recent study report published by the Market Research Future, The global infectious disease treatment market is booming and expected to gain prominence over the forecast period. The market is forecasted to demonstrate a spectacular growth by 2023, surpassing its previous growth records in terms of value with a striking CAGR during the anticipated period (2017 – 2023).

Pathogenic microorganisms, such as bacteria, parasites, viruses or fungi, are the prime cause of infectious diseases. These diseases can also spread indirectly, from one person to another. Most of the infectious diseases consist of minor complications but some other infections such as, AIDS, pneumonia, and meningitis can become life-threatening. According to a study published in the American Journal of Epidemiology and Infectious Disease in 2017, it is observed that a high prevalence of intestinal infection was observed in people living with HIV/AIDS in Cameroon. The major predisposing factors behind this infection includes primary level of education, wells as source of drinking water, ownership of cats as pets, and having a blue collar job.

Notably, increasing research and development expenditure is the key factor driving the infectious disease treatment market. In recent years various companies have introduced various innovative drugs for infectious diseases in the market. For instance, FDA has approved various drugs for Hepatitis B and C treatments such as Baraclude by Bristol-Myers Squibb, Epivir HBV by GlaxoSmithKline, Pegasys by Roche, Harvoni by Gilead, Incivek by Vertex Pharmaceuticals, Mavyret by AbbieVie, and others

Other factors such as, rising prevalence of various infectious diseases, huge research funding for research, and treatment, and rising approval from regulatory bodies are also fuelling the market growth.

Despite these drivers, stringent reimbursement policies, and presence of other fake drugs are expected to decline the market growth.

Global Infectious Disease Treatment Market - Competitive Analysis

The global infectious disease treatment market is currently dominated by few players.

GlaxoSmithKline is one of them by holding a strong share in the market. GSK plc. is a science-led global healthcare company that researches and develops a broad range of innovative products in three primary areas of pharmaceuticals, vaccines and consumer healthcare. As one of the few healthcare companies researching both medicines and vaccines for the World Health Organization’s three priority diseases – HIV/AIDS, tuberculosis and malaria, the company has developed some of the leading global medicines in these fields. On Nov 22, 2017, Johnson & Johnson, and GlaxoSmithKline received FDA approval for an innovative combination of two drugs i.e. Tivicay/rilpivirine and Edurant/dolutegravir, to treat HIV infection.

Merck & Co., Inc. is also one of the leading player in infectious disease treatment market. The company’s stronghold is largely attributed to its innovative and sustainable products. On May 30, 2017, Merck received FDA approval for ISENTRESS® HD used for the treatment of HIV infection in adults, and pediatric patients. On September 06, 2017, Merck & Co., Inc. teamed up with Rigontec to expand its Immuno-Oncology segment.

AbbVie Inc. is another renowned market player in infectious disease treatment market. On August 3, 2017, AbbVie received approval for its Hepatitis C treatment drug, named as Mavyret (glecaprevir and pibrentasvir).

On October 14, 2015, Roche Molecular Systems, Inc. received FDA approval for cobas® HCV laboratory test for the detection of hepatitis C virus (HCV).

Get Full Report at https://www.marketresearchfuture.com/reports/infectious-disease-treatments-market-1626

About US:

Market Research Future (MRFR) enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.

Contact Us:

Market Research Future

Office No. 528, Amanora Chambers

Magarpatta Road, Hadapsar,

Pune - 411028

Maharashtra, India

Phone: +1 646 845 9312

Email: sales@marketresearchfuture.com

Pediatric Medical Device Market Analysis, Market Share, Application Analysis by 2027

 Global Pediatric Medical Devices Market Research Report: Information by Product [Cardiology Devices, In Vitro Diagnostic (IVD) Devices, Diagnostic Imaging Devices, Telemedicine, Anesthesia and Respiratory Care Devices, Neonatal ICU Devices, Monitoring Devices and others], End User (Hospitals, Pediatric Clinics, Ambulatory Surgery Centers, Research and Academic Institutes and others) and Region (Americas, Europe, Asia-Pacific and Middle East & Africa) - Forecast till 2027

Market Highlights

Demand for pediatric medical devices is increasing due to high incidence of chronic illnesses among children, high premature birth rate, increasing birth defects among new born, and rising awareness regarding disease conditions among children. Malnutrition among children prevalent in under developed parts of the world is also a major driver of this market. Global Pediatric medical device market is expected to grow at a CAGR of 10.5% during forecast period 2017 to 2023.

Get Sample Report at https://www.marketresearchfuture.com/sample_request/980

Taste the market data and market information presented in more than 45 market data tables and figures spread over 80 pages of the project report. Avail the in-depth table of content (TOC) & market synopsis on “Pediatric Medical Device Market Research Report –Global Forecast till 2023.”

Global Pediatric Medical Device Market Players

Key players in Pediatric Medical Device Market are Abbott (U.S), General Electric Company (U.S), Johnson & Johnson Private Limited (U.S), Medtronic (Ireland), Siemens AG (Germany), Koninklijke Philips N.V. (Netherland), Novamed (U.S), Phoenix Medical Systems USA (U.S), Phoenix Medical Systems (P) Ltd. (India) and Pega Medical (U.S).

General Electric Company (GE) is an American multinational conglomerate corporation, incorporated in New York. This company operates in segments namely aviation, current, digital, energy connections, global research, healthcare, lighting, oil & gas, power, renewable energy & capital, and all these caters to all needs of financial services, medical devices, life sciences, pharmaceutical, automotive, software development and engineering industries.

Medtronic is a global healthcare solutions company, committed in improving lives of people through its medical technologies, services, and solutions. The union of Medtronic and Covidien demonstrates that thinks differently in solving problems to deliver better health. This company runs on principles of alleviate pain, restore health and extend life of patient. In October 2016, Medtronic got an approval for its suite of cardiac rhythm and heart failure devices, it leads to be scanned in both 3 and 1.5 Tesla (T) magnetic resonance imaging (MRI) machines.

Segmentation

Global Pediatric Medical Device Market Growth  has been segmented on the basis of type of devices which includes infant caps, infant incubators, bili lights, newborn hearing screener, infant warmer, cranial orthosis, atrial septal defect occlude, cerebrospinal fluid shunt, others. Other devices include pulse oximeter for infants and automated external defibrillator. On the basis of end users, the market is segmented into hospitals, pediatric clinics and others.

Regional Analysis

Globally, pediatric medical device market consists of four regions Americas, Europe, Asia Pacific and Middle East & Africa. America is the largest market for pediatric medical devices market whose growth is attributed to availability of wide range of pediatric medical devices, rise in child bearing age among women, and high incidence of chronic illness among children. Europe is the second largest market owing to high prevalence of obesity & other disorders among children as well as availability of funds for research and development activities in healthcare. Asia Pacific shows steady but positive growing owing to increasing awareness regarding child health among women and increasing demand of pediatric medical devices. Middle East & Africa is expected to show high growth in this market due to high prevalence of malnutrition among children and government initiatives to tackle it..

Access Report Details @ https://www.marketresearchfuture.com/reports/pediatric-medical-device-market-980

About US:

Market Research Future (MRFR) enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.

Contact Us:

Market Research Future

Office No. 528, Amanora Chambers

Magarpatta Road, Hadapsar,

Pune - 411028

Maharashtra, India

Phone: +1 646 845 9312

Email: sales@marketresearchfuture.com

Molecular Diagnostics Market 2021 Size, Business Research, Revenue, Growth Insights to 2027

 Molecular Diagnostics Market Report include on MarketReseacrhFuture.com with exhaustive Study. The report aims to provide an overview of Molecular Diagnostics Market Report. The report provides key statistics on the market status. Global Forecast till 2027.

Market Players

Market Research Future (MRFR) recognizes the following companies as key players in the global Molecular Diagnostics Market that include F. Hoffmann-La Roche Ltd (Switzerland), Hologic, Inc. (US), QIAGEN (Europe), Becton, Dickinson and Company (US), Abbott Laboratories (US), Cepheid (US), Siemens (Germany), CLONIT SRL (Italy), Thermo Fisher Scientific(US), Agilent Technologies(California), EKF Diagnostics (UK), Novartis (Switzerland), and Illumina (US).

Get Sample Report at https://www.marketresearchfuture.com/sample_request/1171

Market Highlights

The Global Molecular Diagnostics Market Trends  is expected to register a CAGR of 8.57% during the forecast period, with a market value of USD 16,319.09 Million by 2025.

Molecular diagnostics is a collection of techniques used to analyse biological markers in genome and proteome. It helps to diagnose and monitor the diseases and decide which therapy should be administered to the patient based on the diagnosis. However, the rising prevalence of the infectious disease, increasing awareness regarding molecular diagnostic technique, and advancement in molecular diagnostics are the factors responsible for market growth during the forecast period.

Rising prevalence of infectious diseases, advancements in molecular diagnostic techniques, and increasing prevalence of different types of cancer are likely to contribute to the growth of the market during the assessment period. For instance, as per a survey carried out by the World Health Organisation (WHO), around 9.6 million deaths caused by cancer were recorded in 2018 globally. However, stringent regulatory policies are likely to restrain the market growth during the forecast period.

Segment Analysis

The global molecular diagnostics market has been segmented into product, technique, application, and end user. By product, the market has been segregated into reagents & kits, instruments, and services & software. On the basis of technique, the market has been divided into polymerase chain reaction (PCR), isothermal amplification, hybridization, sequencing, microarray, and others. Based on application, the market has been bifurcated into infectious diseases, oncology, genetic tests, and others. By end user, the market has been categorized as hospitals & clinics, diagnostic laboratories, and others. The hospitals & clinics segment accounted for a market value of USD 4.078.09 million in 2018.

Regional Analysis

The global molecular diagnostics market, based on region, has been classified as the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The Americas is estimated to dominate the global molecular diagnostics market during the forecast period. This is attributed to the increasing geriatric population, and the availability of advanced healthcare facilities in the region play a vital role in the growth of the regional market. The Europe market for molecular diagnostics is expected to be the second-largest during the forecast period. The availability of funds for research & development and rising support from the government toward the life science sector is expected to boost the growth of the market in this region.

Browse Full Report Details @ https://www.marketresearchfuture.com/reports/molecular-diagnostics-market-1171

Additionally, the companies operating in the market are mainly focusing on mergers & acquisition, which is expected to support market growth. Asia-Pacific is estimated to be the fastest-growing market due to developing economies such as China, India, and South Korea emerging as major destinations for the outsourcing of clinical trials, drug manufacturing, and pathology testing. In addition to this, improving healthcare infrastructure has increased the number of research activities in the region. Moreover, in Asia-Pacific, China accounted for a market share of 21.4% in 2018. Furthermore, the market in the Middle East & Africa is expected to witness steady growth during the review period due to the lack of awareness regarding healthcare facilities.

About US:

Market Research Future (MRFR) enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.

Contact Us:

Market Research Future

Office No. 528, Amanora Chambers

Magarpatta Road, Hadapsar,

Pune - 411028

Maharashtra, India

Phone: +1 646 845 9312

Email: sales@marketresearchfuture.com

Nuclear Imaging Devices Market 2021 Global Overview, Regional Analysis, Size, Share and Forecast to 2027

 Global Nuclear Imaging Devices Market Research Report: Information by Technology (PET, SPECT (Hybrid SPECT Systems and Standalone SPECT Systems) and Planar Scintigraphy)), Application (Oncology, Cardiology, Neurology and others), End User (Hospitals, Diagnostic Imaging Centers and others) and Region - Global Forecast till 2027

Market Highlights

The global Nuclear Imaging Devices Market Size is expected to grow significantly over the forecast period. It is anticipated that the market held a valuation of USD 2490 million in 2018 and is projected to register a CAGR of 5.2% over the forecast period.

The increasing prevalence of cardiovascular disorders is one of the key factors driving the nuclear imaging devices market. As per the report published by the Centers for Disease Control and Prevention (CDC) in 2017, nearly 92.1 million adults were dealing with at least one type of cardiovascular disease.

Get Sample Report at https://www.marketresearchfuture.com/sample_request/8014

Various other factors such as the advancements in radiotracers, acceptance of nuclear imaging devices in ambulatory settings, increasing geriatric population, untapped emerging markets, rise in regulatory approvals, and increasing investment on diagnostic imaging centers are also expected to propel the growth of the market.

However, the high cost of the nuclear imaging device, shorter half-life of radiopharmaceuticals can hamper market growth over the forecast period.

Key Players

Some of the key players in the global nuclear imaging devices market are Philips Healthcare, Digirad Corporation, Neusoft Medical Systems Co., Ltd., Progenics Pharmaceuticals Inc., Cannon Inc., Surgiceye GmbH, CMR Naviscan, Mediso Medical Imaging Systems Ltd., Agfa-Gevaert Group, General Electric Company, DDD-Diagnostic A/S, Spectrum Dynamics Medical, FMI Medical Systems, Inc., Segamicorp, and others.

Segmentation

The global nuclear imaging devices market is segmented based on technology, application, end user, and region.

The global market for nuclear imaging devices, by technology, is segmented into positron emission tomography (PET), single photon emission computed tomography (SPECT), and planar scintigraphy. The single-photon-emission computed tomography (SPECT) are further classified as hybrid SPECT systems and standalone SPECT systems.

Based on application, the market is segmented into oncology, cardiology, neurology, and others.

Based on end user, the market is segmented into hospitals, diagnostic imaging centers, and others.

The diagnostic imaging centers segment is expected to witness the fastest growth over the forecast period due to rising adoption of nuclear imaging in diagnostic centers.

Regional Analysis

In the current scope of the study, the segments mentioned above are covered into the four global regions, namely, the Americas, Europe, Asia-Pacific, and the Middle East and African region.

The nuclear imaging devices market in the Americas has further been segmented into North America and South America, with the North American market divided into the US and Canada.

The European nuclear imaging devices market has been segmented into Western Europe and Eastern Europe. Western Europe has been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe.  The nuclear imaging devices market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The nuclear imaging devices market in the Middle East & Africa has been segmented into the Middle East and Africa.

Access Report Details @ https://www.marketresearchfuture.com/reports/nuclear-imaging-devices-market-8014

About US:

Market Research Future (MRFR) enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.

Contact Us:

Market Research Future

Office No. 528, Amanora Chambers

Magarpatta Road, Hadapsar,

Pune - 411028

Maharashtra, India

Phone: +1 646 845 9312

Email: sales@marketresearchfuture.com

Wound Care Biologics Market 2021 Growing Trend and Demand in Healthcare Sector 2027

 Global Wound Care Biologics Research Report: Information by Product Type (Biological Skin Substitutes, Topical Agents), by Wound Type (Surgical and Traumatic Wounds, Diabetic Foot Ulcer, Pressure Ulcers), End User (Hospitals, Clinics)—Forecast till 2027

Competitive Landscape:

Some of the major players in the global wound care biologics market include Solsys Medical (US), ACell (US), Organogenesis (US), Anika Therapeutics (US), Integra LifeSciences Corporation (US), MiMedx Group (US), Kerecis (Iceland), Vericel Corporation (US), Marine Polymer Technologies, Inc. (US), Wright Medical (US), Mölnlycke Health Care AB (Sweden), Osiris Therapeutics (US), and Smith & Nephew (UK).

Wound Care Biologics Market Overview:

The global wound care biologics market stood at USD 1.20 Bn in 2017 and is touted to expand at a CAGR of 9.9% over the forecast period of 2018-2023, reveals Market Research Future (MRFR) in a detailed research report. The field of wound care biologics includes growth factors, skin substitutes, collagen dressings, etc. which assist in creating an active healing environment for the healing of wounds naturally.

Get Sample Report at https://www.marketresearchfuture.com/sample_request/6563

Various factors have been instrumental in shaping the growth of the global Wound Care Biologics Market Trends. Among them, rising incidences of burn injuries constitute for a major factor. Wound care biologics are gaining popularity as a treatment modality for the management of burn injuries where there is insufficient skin for grafting. Wound care biologics can provide temporary or permanent coverage of burn wounds, with the advantage of availability in large quantities and little or no risk of immunologic issues or infection.

Rapid growth in the global geriatric population acts as a fuel for the growth of the global wound care biologics market. The rapid growth in the geriatric population will raise the incidences of chronic wounds which would consequently boost the demand for wound care biologics product.

Rising prevalence of diabetic foot ulcers has contributed significantly to the growth of the global wound care biologics market. Global prevalence of diabetes augments the chances of patients developing diabetic ulcers which can have severe implications if untreated.

Raising awareness regarding the availability of wound care biologics, rising standards of livings and greater affordability further supports the growth of the market.

Innovations such as PDGF, RegranexTM, MicroRNA-based therapeutics, small molecule antagonists, use of biomarkers, and VEGF- and GM-CSF-based cosmeceuticals in the field of wound care biologics spurred the growth of the market. However, such as options are associated with high failure rate, and there remain large unmet needs for new effective treatments for acute wounds which are likely to restrain the growth of the market over the forecast period. High costs of wound care biologics and stringent regulatory norms for approval remain major hurdles for the growth of the global wound care biologics market. Meanwhile, improving reimbursement policies is expected to provide growth opportunities to the market over the forecast period.

Segmentation:

The global wound care biologics market has been segmented based on product type, wound type, and end user.

By product type, the market has been segmented into biological skin substitutes and topical agents. The biological skin substitutes segment was the largest as well as the fastest growing segment in 2017.

By wound type, the market has been segmented into ulcers, surgical & traumatic wounds, and burns. The ulcers segment has been further segmented into diabetic foot ulcers, pressure ulcers, venous leg ulcer, and others.

By end user, the market has been segmented into hospitals, ambulatory surgical centers, and clinics.

Regional Analysis

The Americas, Europe, Asia-Pacific, and the Middle East & Africa are the key markets for wound care biologics. The Americas dominate the global wound care biologics market, the US and Canada being the key contributors to the Americas market. Robust healthcare sector, growing prevalence of diabetes, rising incidences of accidents and high healthcare expenditure support the growth of the Americas market for wound care biologics.

Europe accounts for the second largest share of the market on account of growing prevalence of chronic diseases and burns cases in the region.

Asia Pacific market is touted to be the fastest growing market for wound care biologics. Presence of a large base of the diabetic population and advances in the healthcare sector contribute to the growth of the market.

The Middle East & Africa market is expected to exhibit sluggish growth owing to the limited availability of healthcare facilities and lack of affordability and awareness.

Get Full Report at https://www.marketresearchfuture.com/reports/wound-care-biologics-market-6563

About US:

Market Research Future (MRFR) enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.

Contact Us:

Market Research Future

Office No. 528, Amanora Chambers

Magarpatta Road, Hadapsar,

Pune - 411028

Maharashtra, India

Phone: +1 646 845 9312

Email: sales@marketresearchfuture.com

Global Mitral Valve Stenosis Market 2021 Industry Analysis, Share, Growth, Trends and Forecast 2027

 Mitral Valve Stenosis Market Research Report: By Diagnostic Test (Electrocardiogram, Transthoracic Echocardiogram, Cardiac Catheterization), by Treatment (Medication, Procedure), by End User (Hospital, Diagnostic Centers) - Global Forecast till 2027

Market Highlights

The global Mitral Valve Stenosis Market Trends  is anticipated to grow significantly over the forecast period 2018 to 2023. Mitral valve stenosis occurs when then the mitral valve opening in the heart is narrowed. The mitral valve is located on the left side of the heart between the two chambers namely the atrium and the ventricle. In this condition, enough amount of blood does not flow through the mitral valve. Scarring caused by rheumatic fever is considered to be the major cause of mitral valve stenosis. The growing prevalence of heart diseases, increasing occurrences of rheumatic fever, technological advancements coupled with the introduction of novel mitral valves are anticipated to boost the growth of the market during the assessment period. According to a study by researchers at the Stanford University School of Medicine in 2017, it was found that more than 50,000 people in the United States undergo either aortic- or mitral valve replacement surgery each year. On the other hand, the stringent government regulation for drug and medical device approval and the high cost of mitral valve surgeries may hamper the growth of the market.

Get Sample Report at https://www.marketresearchfuture.com/sample_request/6560

Key Players

Some of the key players in the global mitral valve stenosis market are Medtronic Plc, Edward Lifesciences, Boston Scientific Corporation, Abbott Laboratories, HighLife Medical, Neovasc Inc., CryoLife, Inc., On-X Life Technologies, Inc., Braun Melsungen AG, JenaValve Technology, Siemens Healthcare, and Micro Interventional Devices, Inc.

Segmentation

The global mitral valve stenosis market has been segmented into diagnostic tests, treatment, and end user.

The global market, on the basis of diagnostic tests, has been segmented into electrocardiogram (ECG), transthoracic echocardiogram, transesophageal echocardiogram, cardiac catheterization, and others.

The global market, on the basis of treatment, has been segmented into medication and procedures. The medication segmented is further classified into diuretics, blood thinners, beta blockers, anti-arrhythmic drugs, and antibiotics. The procedures segment has been further segmented into mitral valvuloplasty and mitral valve surgery. The mitral surgery segment has been further classified into mitral valve repair and mitral valve replacement. The procedures segment is anticipated to hold the largest market share on the basis of treatment due to the growing number of companies engaged in the development of medical devices for mitral valve stenosis.

The global market, by end user, has been segmented into hospital & clinics, diagnostic centers, and others.

Regional Analysis

The market in the Americas is expected to dominate the global mitral valve stenosis market. The market growth in this region is majorly attributed to the presence of well-established healthcare sector, rising prevalence of cardiac diseases, increasing preference for minimally invasive surgeries, and growing healthcare expenditure. Europe is anticipated to hold the second largest position in the global mitral valve stenosis market. The market growth in this region is attributed to the increasing prevalence of heart diseases and rising expenditure for the healthcare sector. According to the UK factsheet August 2018 by the British Heart Foundation, there are about 7 million people living with heart and circulatory diseases in the UK. Asia-Pacific mitral valve stenosis market is anticipated to be the fastest growing market. Rising burden of heart diseases, improvement in clinical trial regulations, increasing preference for advanced medical technologies, the rise in medical tourism, and increasing investments in the healthcare sector are anticipated to drive the market growth in this region. The Middle East & Africa has the least market share in the global mitral valve stenosis market.

Access Report @  https://www.marketresearchfuture.com/reports/mitral-valve-stenosis-market-6560

About US:

Market Research Future (MRFR) enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.

Contact Us:

Market Research Future

Office No. 528, Amanora Chambers

Magarpatta Road, Hadapsar,

Pune - 411028

Maharashtra, India

Phone: +1 646 845 9312

Email: sales@marketresearchfuture.com